umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients
Department of Experimental Physiology, Medical School, University of Athens.
First Oncology Clinic, Errikos Dunant Hospital, Athens.
Department of Experimental Physiology, Medical School, University of Athens.
Department of Experimental Physiology, Medical School, University of Athens.ORCID iD: 0000-0001-8191-6659
Show others and affiliations
2012 (English)In: Oncology Reports, ISSN 1021-335X, E-ISSN 1791-2431, Vol. 28, no 6, p. 2255-2263Article in journal (Refereed) Published
Abstract [en]

Gene expression patterns as well as gene interactions are under investigation for their involvement in tumour heterogeneity. The molecular classification of breast cancer based on hormone receptor expression, grade and HER2 receptor levels, is indicative but not adequate enough to complete the prognostic data. The objectives of this study were to validate the prognostic value of 19 genes, solely, and as parts of classifiers (sets of genes), in breast cancer patients and to determine whether the expression of these genes and classifiers is correlated with breast cancer molecular classification. Gene expression was examined in the blood of 88 breast cancer patients and 50 healthy controls using multiplex quantitative real-time PCR. Patients with a second primary malignancy showed a statistically significant difference when compared with: i) patients with a single breast cancer, for an 8-gene classifier (p<0.02); and ii) healthy individuals (classifier FBX033, FLJ339115) (p<0.01), with respect to gene expression. The classifier ENY2, USP38 was associated with the development of primary breast cancer. A newly established classifier (ENY2, USP38, RPS7, Osbpl-1 and ETF1) indicated a statistically significant association with HER2 subtype patients, compared to patients with a different molecular classification (p<0.04). The gene FLJ33915 was differentially expressed in a subgroup of HER2-positive patients with infiltrated axillary lymph nodes (p<0.028). We validated the prognostic value of 4 classifiers for primary and second primary malignancy. Evidence of a classifier predicting the HER2 subtype and the gene FLJ33915 which subdivides HER2 subtype patients is also presented.

Place, publisher, year, edition, pages
2012. Vol. 28, no 6, p. 2255-2263
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-145558DOI: 10.3892/or.2012.2018OAI: oai:DiVA.org:umu-145558DiVA, id: diva2:1189411
Available from: 2018-03-09 Created: 2018-03-09 Last updated: 2018-06-09

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Theos, Apostolos

Search in DiVA

By author/editor
Theos, Apostolos
In the same journal
Oncology Reports
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 262 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf